3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
5
Medulloblastoma
3
Colonic Neoplasms
3
Turcot syndrome
2
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Neuroblastoma
2
Ependymoma
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Locally Advanced Rectal Cancer
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Celecoxib
×
1 year
×
Clear all
NCT06903858
2026-05-22
PICC-3
Sun Yat-sen University
Phase 2
Recruiting
105 enrolled
NCT03926338
2025-11-20
PICC
Sun Yat-sen University
Phase 2
Recruiting
270 enrolled